DiaMedica Therapeutics to Announce Q1 2024 Financial Results and Business Update on May 9, 2024

MINNEAPOLIS-- DiaMedica Therapeutics, Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing recombinant KLK1 (DM199) for treating acute ischemic stroke, announced it will release its first quarter 2024 financial results after the markets close on Wednesday, May 8th. DiaMedica has scheduled a live conference call on Thursday, May 9th at 7:00 AM Central Time to provide a business update and discuss these financial results.

The conference call details are as follows:
- Date: Thursday, May 9, 2023
- Time: 7:00 AM CT / 8:00 AM ET
- Web access:
- Dial In: (646) 357-8785
- Conference ID: 07657

Interested parties can access the call by dialing in or listening to the simultaneous webcast. Attendees are advised to log on to the website or dial in 15 minutes before the call begins. The webcast will be available for replay on DiaMedica’s website under the investor relations section, specifically under events and presentations, for 12 months following the earnings call. Additionally, a telephonic replay will be accessible until May 16, 2024, by dialing (888) 660-6345 (US Toll Free) with the replay passcode: 07657#.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical firm dedicated to enhancing the lives of individuals suffering from serious medical conditions, with a primary focus on acute ischemic stroke. The company's leading candidate, DM199 (rinvecalinase alfa), is the first pharmaceutically active synthetic form of the KLK1 protein. This protein is a well-established therapeutic agent in Asia for treating acute ischemic stroke and other vascular diseases.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!